ERBB2 and breast carcinoma: The EGFR is an important mediator of tumor development and progression, whereas IL-17E affects cell cycle progression, both in TNBC cells and in other breast cancer cells, such as human epidermal growth factor receptor 2 (HER2)-positive tumor cells [15].